Aptose Biosciences (TSE:APS) Share Price Passes Above 50 Day Moving Average – What’s Next?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$2.18 and traded as high as C$2.25. Aptose Biosciences shares last traded at C$2.25, with a volume of 100 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners downgraded Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Aptose Biosciences Stock Performance

The firm’s fifty day moving average price is C$2.18 and its 200 day moving average price is C$1.94. The firm has a market cap of C$5.74 million, a P/E ratio of 3.26 and a beta of -1.05. The company has a debt-to-equity ratio of -117.37, a quick ratio of 5.41 and a current ratio of 1.05.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its quarterly earnings data on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share (EPS) for the quarter. Sell-side analysts expect that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.